Peptide Atlas · Mineral

Ferric carboxymaltose

In the AFFIRM-AHF trial of 1,108 patients stabilised after acute heart failure with iron deficiency, intravenous ferric carboxymaltose lowered total heart failure hospitalisations against placebo (rate ratio 0.74) without changing cardiovascular death.

established

provisional
2 citations
0 discussions
0 followers
FCM
Ferinject
Injectafer
iron(III) carboxymaltose

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Ferric carboxymaltose. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Ferric carboxymaltose causes far more hypophosphatemia than iron isomaltoside (two RCTs)	established	pmid 32016310
Ferric carboxymaltose reduced heart failure hospitalisations after acute heart failure (AFFIRM-AHF)	established	pmid 33197395

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.